Two patients with multiple myeloma in relapse after allogeneic BMT received donor lymphocyte infusions (DLI) but later required chemotherapy for treatment of myeloma-related complications. In both patients, recovery from chemotherapy-induced aplasia was accompanied by manifestations of graft-versus-host reactions. The first patient developed grade II acute GVHD and a complete remission which has lasted Ͼ22 months. The second patient developed grade III acute GVHD but died with co-existing GVHD and extensive extramedullary myeloma. These results demonstrate that chemotherapy does not nullify the ability of donor lymphocytes to mediate graft-versus-host reactions. Keywords: multiple myeloma; bone marrow transplantation; leukocyte transfusions; chemotherapy; graft-versusmyeloma; graft-versus-host disease Malignancies that relapse after BMT are rarely curable by cytotoxic chemotherapy alone 1 and tend to progress rapidly. DLI can induce remissions in the post-BMT setting, but the time to respond to this form of therapy ranges from 16 to 241 days.
Malignancies that relapse after BMT are rarely curable by cytotoxic chemotherapy alone 1 and tend to progress rapidly. DLI can induce remissions in the post-BMT setting, but the time to respond to this form of therapy ranges from 16 to 241 days. 2 Therefore, patients may develop complications of disease before graft-versus-tumor effects are manifest. Although such patients may benefit from palliative chemotherapy, the effect of cytotoxic drugs on the ability of DLI to produce either remissions or GVHD is not known. The cases described below illustrate the principle that at least some of the cells that mediate graft-versus-host reactions can withstand chemotherapy.
Case 1
A 42-year-old man was diagnosed in 1989 with a left temporal plasmacytoma and received 4500 cGy local irradiation. One year later, a skeletal survey showed lytic lesions, a bone marrow aspirate revealed plasmacytosis, and serum and urine contained monoclonal lambda () immunoglobulin light chains. The patient obtained a partial response to treatment with melphalan and prednisone and in July 1991, he received a BU/CY preparative regimen followed by an elutriated BMT 3 from an HLA-identical brother. CsA was administered for 170 days following transplantation and no GVHD occurred.
In July 1995, the patient returned for evaluation of back pain and was found to have lytic spine lesions, recurrent marrow plasmacytosis and 25-30% host-derived cells by RFLP analysis. He received radiation to his back and pamidronate for subsequent episodes of hypercalcemia. On day 93 after relapse, the patient received 10 7 donor CD3 + T cells/kg. Four weeks later, the patient experienced a spontaneous rib fracture. Serum creatinine was 4.0 mg/dl, and a 24-h urine collection contained 28.8 g of protein ( Figure 1 ). He received two cycles of chemotherapy with vincristine, adriamycin and dexamethasone (VAD) and experienced immediate symptomatic improvement. However, monoclonal light chains were still found in a urine specimen obtained 23 days after the completion of chemotherapy (Figure 2 , left lane), and the bone marrow contained 3-5% residual host cells by RFLP analysis. Sixteen days later, the patient developed a Hickman catheter infection and skin rash; the serum AST was 505 IU/l (normal range 0-35 IU/l), alkaline phosphatase was 763 IU/l (normal range 30-120 IU/l), and total bilirubin was 3.1 mg/dl (normal range 0.2-1.2 mg/dl). Treatment with antibiotics, CsA and methylprednisolone (MP) was initiated. Histologic examination of a skin biopsy revealed basal vacuolization and keratinocyte necrosis, and a liver biopsy demonstrated lymphocytic infiltration of the portal tracts associated with bile duct epithelial injury. These findings were consistent with acute grade II GVHD. At the time of GVHD, the CD4/CD8 T cell ratio was 0.23:1 (compared to 2.3:1 before DLI), CD56
+ cells had increased from 5% before DLI to 20% of total mononuclear cells, and NK and LAK cell activity were also increased (A Seber, manuscript in preparation). A repeat urine immunofixation electrophoresis (UIFE) obtained 116 days after DLI showed no evidence of monoclonal gammopathy (Figure 2 , right lane) and bone marrow cells were exclusively donor-derived. Immunosuppression was gradually tapered. GVHD did not recur, and the patient remains in remission by UIFE with 100% donor hematopoietic chimerism 847 days after DLI.
Case 2
A 58-year-old woman presented in September 1994 with spontaneous rib fractures. She was found to have biclonal and light chain multiple myeloma and received three cycles of VAD chemotherapy. In February 1995, she received an elutriated, HLA-identical sibling allograft 4 following a BU/CY preparative regimen. GVHD did not occur and CsA was discontinued 80 days after BMT. However, monoclonal + plasma cells were detected in bone marrow specimens obtained 4 and 8 months after transplant.
The patient developed a painful sternal lesion 514 days after BMT and plasma cells comprised 50% of a bone marrow biopsy specimen. She received one cycle of VAD chemotherapy with only minimal symptomatic improvement. Thirty-four days after symptomatic progression, the patient received 10 7 donor T cells/kg. Within 1 month, she was found to have plasma cell leukemia and received CY 60 mg/kg i.v. followed in 4 days by 10 8 donor T cells/kg. Three weeks later, the patient became unresponsive, hypotensive, and hypoxic. Chest radiograph revealed bilateral pulmonary infiltrates and peripheral blood smear revealed recurrent plasma cell leukemia. She was intubated, treated with steroids and broad spectrum antibiotics and received CY 60 mg/kg i.v. 2 and 8 days after intubation. Upon hematologic recovery, 15 days after the last dose of CY, the patient developed an extensive skin rash, and biopsy showed diffuse basal vacuolization, necrotic keratinocytes, and a brisk mononuclear cell exocytosis into the epidermis consistent with acute grade III GVHD. Peripheral blood plasmablasts were now absent. She was placed on MP 1 mg/kg/day with prompt resolution of the skin rash. However, a pleural fluid sample obtained 21 days later for evaluation of persistent fever contained 2%
+ monoclonal plasma cells, and a bone marrow biopsy performed 102 days after the first DLI still contained approximately 5% monoclonal plasma cells. Six days later, the patient developed diarrhea; colonoscopy revealed the presence of both atypical plasma cells and apoptotic epithelial cells suggestive of mild GVHD. However, progressive hypoalbuminemia, hypotension and respiratory failure ensued, and the patient died 156 days after the first DLI.
Discussion
DLI is a promising therapy that can induce remissions in a variety of hematologic malignancies in relapse after allogeneic BMT. 2, 5, 6 Treatment should begin promptly upon confirmation of relapse or progression after BMT, because relapsed disease may progress rapidly and because responses to DLI may take weeks to months. 2, 7 Unfortunately, initiation of DLI was delayed in both patients by several weeks, and life-threatening illness supervened within 1 month after DLI. Chemotherapy was given for symptom palliation without regard for its effects on the recently donated lymphocytes. Surprisingly, in both patients recovery from chemotherapy-induced aplasia was accompanied by clinical evidence of graft-versus-host reactions. In the first patient, grade II acute GVHD of the skin and liver occurred upon recovery from the second and last cycle of VAD chemotherapy. Moreover, residual myeloma was present after completion of VAD chemotherapy, but disappeared after the development of GVHD, suggesting that antitumor lymphocytes survived the chemotherapy. In this patient, eradication of residual myeloma was documented by urine immunofixation electrophoresis after steroid treatment of acute GVHD was initiated. Thus, while we cannot exclude the possibility that steroids and not lymphocytes induced the remission, the length of the remission suggests that donor lymphocytes have at the very least played a role in maintaining it. In the second patient, GVHD followed hematologic recovery from cyclophosphamide, but it had little or no effect against her tumor cells. In particular, GVHD was ineffective at eliminating extramedullary disease, which may be less susceptible to the effects of DLI. 8 The ability of activated donor lymphocytes to resist the lethal actions of chemotherapy, including high-dose corticosteroids and CY, runs counter to the known immunosuppressive activities of these drugs in vivo. However, some T cells are quite resistant to very high doses of chemotherapy or radiation, such as host T cells that are capable of mediating allogeneic bone marrow rejection despite lethal BMT conditioning regimens. 9 Studies in dogs and humans also suggest that priming of host T cells, for instance by transfusion, 10, 11 increases their resistance to chemotherapy and radiation. We believe that the clinical scenarios described represent the obverse of this situation. In our patients, the transfused donor cells are primed in vivo to the minor histocompatibility antigens expressed by a recipient that is already tolerant of the donor. By the time CY or VAD is administered more than 1 week later, some host-reactive cells have become resistant to the lethal effects of chemotherapy and remain capable of causing both GVHD and graft-versus-tumor effects. Alternatively, or in addition, the effects of chemotherapy on host cells may enhance the capacity of donor cells to induce GVHD, for instance by creating more 'space' for engraftment.
The management of patients who have received DLI can be quite challenging. Because DLI can produce long-term remissions, every effort should be made to support the patient until the therapy has had a chance to work. Unfortunately, the median time to complete remission is 34 days in acute leukemia and 85 days in CML. 2 Thus, diseaserelated complications may arise before a response to or failure of DLI can be clearly documented. We believe that the clinical courses of the two patients described herein illustrate two general principles. First, if DLI is to be given for treatment of post-BMT relapse, therapy should commence promptly, lest the disease progress significantly or spread to extramedullary sites. Second, should disease complications arise following initiation of DLI, chemotherapy may be given to the patient without precluding the possibility of acute GVHD, graft-versus-tumor effects or even longterm remission.
